Trust Co of Kansas Increases Position in Danaher Co. (NYSE:DHR)

Trust Co of Kansas increased its stake in shares of Danaher Co. (NYSE:DHR) by 8.0% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,183 shares of the conglomerate’s stock after purchasing an additional 161 shares during the quarter. Danaher makes up 0.2% of Trust Co of Kansas’ holdings, making the stock its 28th largest position. Trust Co of Kansas’ holdings in Danaher were worth $501,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors also recently added to or reduced their stakes in the stock. Benjamin Edwards Inc. increased its stake in Danaher by 1.8% during the 2nd quarter. Benjamin Edwards Inc. now owns 2,153 shares of the conglomerate’s stock worth $538,000 after buying an additional 38 shares in the last quarter. Wedge Capital Management L L P NC increased its position in shares of Danaher by 3.2% during the third quarter. Wedge Capital Management L L P NC now owns 1,231 shares of the conglomerate’s stock worth $342,000 after purchasing an additional 38 shares in the last quarter. Certified Advisory Corp raised its stake in Danaher by 4.5% in the 2nd quarter. Certified Advisory Corp now owns 926 shares of the conglomerate’s stock valued at $231,000 after purchasing an additional 40 shares during the last quarter. Meridian Financial Partners LLC lifted its holdings in Danaher by 4.4% in the 3rd quarter. Meridian Financial Partners LLC now owns 957 shares of the conglomerate’s stock valued at $266,000 after purchasing an additional 40 shares in the last quarter. Finally, Kovack Advisors Inc. boosted its stake in Danaher by 3.4% during the 3rd quarter. Kovack Advisors Inc. now owns 1,243 shares of the conglomerate’s stock worth $346,000 after purchasing an additional 41 shares during the last quarter. Institutional investors own 79.05% of the company’s stock.

Danaher Price Performance

DHR stock opened at $238.41 on Friday. The stock has a market cap of $172.20 billion, a price-to-earnings ratio of 45.50, a PEG ratio of 4.23 and a beta of 0.83. Danaher Co. has a fifty-two week low of $222.53 and a fifty-two week high of $281.70. The company has a quick ratio of 1.01, a current ratio of 1.37 and a debt-to-equity ratio of 0.32. The business has a 50 day moving average price of $234.99 and a 200 day moving average price of $253.37.

Danaher (NYSE:DHR) last issued its quarterly earnings data on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share for the quarter, topping the consensus estimate of $1.57 by $0.14. Danaher had a net margin of 16.39% and a return on equity of 10.62%. The business had revenue of $5.80 billion during the quarter, compared to the consensus estimate of $5.59 billion. During the same quarter in the previous year, the firm earned $2.02 EPS. The company’s revenue was up 3.1% compared to the same quarter last year. Equities research analysts anticipate that Danaher Co. will post 7.49 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Friday, December 27th will be issued a $0.27 dividend. This represents a $1.08 annualized dividend and a dividend yield of 0.45%. The ex-dividend date of this dividend is Friday, December 27th. Danaher’s payout ratio is currently 20.61%.

Wall Street Analysts Forecast Growth

DHR has been the subject of a number of recent research reports. StockNews.com cut shares of Danaher from a “buy” rating to a “hold” rating in a research report on Saturday, December 14th. KeyCorp lifted their price target on Danaher from $290.00 to $310.00 and gave the stock an “overweight” rating in a report on Wednesday, October 23rd. Wolfe Research raised shares of Danaher from a “peer perform” rating to an “outperform” rating and set a $285.00 price objective for the company in a report on Thursday, October 31st. Guggenheim assumed coverage on shares of Danaher in a research note on Thursday, December 19th. They set a “buy” rating and a $275.00 target price on the stock. Finally, Bank of America raised shares of Danaher from a “neutral” rating to a “buy” rating and set a $290.00 price target for the company in a research note on Friday, December 13th. Six investment analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $286.80.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.